Sone-214 [patched] -

| Year | Milestone | |------|-----------| | | Target validation of BACE1 for AD; Sone Biopharma initiates a hit‑to‑lead program. | | 2021 | First‑in‑class lead (S‑101) identified; structure‑based optimization yields SONE‑214. | | 2022 | Patent filed (WO 2022/134567 A1). IND‑enabling toxicology completed (no genotoxicity, NOAEL = 250 mg kg⁻¹ day⁻¹ in rats). | | 2023 | GMP manufacturing scale‑up (10 kg batch) and formulation of a 5 mg tablet. | | 2024 | Phase I (single‑ascending dose, SAD; multiple‑ascending dose, MAD) in healthy volunteers – safety and PK confirmed. | | 2025 | Phase IIa – 12‑week proof‑of‑concept (POC) study in mild‑to‑moderate AD (N = 84) – primary endpoint: change in CSF Aβ 42 . | | 2026 | Phase IIb/III – Adaptive design trial (N = 420) evaluating cognitive outcomes (ADAS‑Cog13) and disease‑modifying biomarkers. |

As researchers and cybersecurity experts continue to investigate the enigma that is SONE-214, several questions remain unanswered: SONE-214

4.5/5 Stars

The identifier SONE-214 typically refers to a specific DVD or digital release. While the exact details of the video—such as the featured actress or specific theme—can vary based on the release timeline, works under the S1 label generally focus on: | Year | Milestone | |------|-----------| | |